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Enhanced target organ damage and cardiovascular morbidity represent common issues observed in both resistant hypertension
andobstructivesleepapnea.Commonpathophysiologicalfeaturesandriskfactorsjustifytheircoexistence,especiallyinindividuals
with increased upper-body adiposity. Impaired sodium handling, sympathetic activation, accelerated arterial stiﬀening, and
impaired cardiorenal hemodynamics contribute to drug-resistant hypertension development in obstructive sleep apnea. Eﬀective
C P A Pt h e r a p yq u a l i ﬁ e sa sa ne ﬀective “add-on” to the underlying antihypertensive pharmacological therapy, and emerging
evidence underlines the favorable eﬀect of mineralocorticoid antagonists on both resistant hypertension and obstructive sleep
apnea treatment.
1.Introduction
In the recent years several original articles and review
papers have focused on the association between arterial
hypertension and obstructive sleep apnea syndrome (OSA)
[1–4]. Such an association is supported by the interplay
of common risk factors and pathophysiological pathways
aﬀecting both the vascular wall and the upper airway [5].
Regarding risk factors, the obesity epidemic has prompted
therecognitionofaninteraction betweenOSAand increased
blood pressure (BP) [6]; additionally, as the population ages
and gains weight, resistant hypertension is becoming more
prevalent [7].
Up to date few small epidemiological studies have shown
a signiﬁcant association between resistant hypertension and
OSA, and based on that both the Seventh Report of the
Joint National Committee and the 2007 European Society of
Cardiology-European Society ofHypertension guidelinesfor
the management of arterial hypertension recognized OSA as
an identiﬁable and not uncommon cause of resistant hyper-
tension [8, 9]. Surprisingly, the European guidelines added
OSA to the causes of secondary hypertension, thus creating
some confusion; indeed, it is yet unresolved whether OSA
could represent just a bystander of essential hypertension
and whether the gold standard therapeutic approach for
OSA,namely, continuouspositive airway pressure (CPAP),is
accompanied by eﬃcacious treatment of hypertension [4, 5].
Either way, misdiagnosed or inappropriately treated OSA
may prevent pharmacological treatment of drug-resistant
essential hypertension from reducing BP levels within the
goal [10].
In the present paper, we illustrate the pathophysiological
and epidemiological evidence that supports the interrela-
tionship between resistant hypertension and OSA and how
these observations could be translated in clinical decisions in
the context of an outpatient hypertension clinic.
2.PathophysiologicalIssues
2.1. Obesity. Subjects with increased body size are more
likely to suﬀer from hypertension and exhibit diﬃcult-
to-control hypertension compared to nonobese controls2 International Journal of Hypertension
[11–13]. Increased free leptin is at least partly associated
with increased central and peripheral sympathetic ﬁring
in experimental animal models [14, 15], while nonapneic
and nonobese subjects with out-of-oﬃce hypertension are
characterized by hyperleptinemia with respect to their
normotensive counterparts [16]. Therefore, it is plausible
that leptin could represent an accelerator of sympathetic
activation in both obesity and hypertension alone. Obesity
itselfisfrequentlyobservedinOSApatientsin whom sympa-
thetic activation is further augmented by episodic nocturnal
hypoxia and hypercapnia due to the repetitive collapse of
the upper vulnerable airway, yet whether leptin levels are
raised in normotensive nonobese patients with OSA is still
debated [17]. Additionally, sympathetic overactivity per se
is accompanied by BP and heart rate increases, as well
as by enhanced sodium retention. The above operating
mechanisms in obese hypertensive patients with OSA are
at least partly responsible for the increased hemodynamic
load, and frequently three or more drugs in the maximum
tolerated doses are insuﬃcient to eﬀectively reduce BP levels.
2.2. Kidney Function. Focusing on the kidney in obese sub-
jects, “pressure natriuresis” is impaired, and higher BP levels
are required to achieve sodium balance [18]. Additionally,
urinary albumin excretion isincreased inobese OSApatients
with hypertension compared to hypertensive nonOSA con-
trols [19]. A further hypothetical mechanism by which OSA
aﬀects renal hemodynamics is that the continuous nocturnal
intrathoracic pressure swings are accompanied by changes
in systemic and renal venous pressure, as it has been shown
that renal venous congestion is accompanied by a decline
in kidney function in patients with both preserved and
impaired cardiac function undergoing right heart catheter-
ization [20]. Considering the above, kidney impairment in
OSA subjects may contribute to the development of drug-
resistant hypertension, and diuretics implementationmay be
accompaniedbybetterantihypertensive resultsbypromoting
both sodium excretion and venous decongestion.
2.3. Aldosterone. Plasma aldosterone levels are increased in
both obese hypertensive patients and those with OSA [6].
Renin-angiotensin-aldosterone axis activation is implicated
in most hypertensive states, and apart from sympathetic
overdrive, visceral adiposity could also participate in that
phenomenon by mechanisms that have not yet been fully
elucidated [21]. In patients with resistant hypertension who
were referred to an outpatient hypertensive unit, those with
a high clinical suspicion for OSA exhibited increased plasma
aldosterone levels with respect to those with no symptoms
of OSA. In those with a ﬁnal positive diagnosis of OSA as
well as in obese hypertensive subjects, renin activity was
suppressed, a ﬁnding that suggests that aldosterone secretion
is at least partly plasma renin independent; thus, in resistant
hypertensive patients with OSA targeting of renin inhibition
seems pathophysiologically a less justiﬁed therapeutic strat-
egy compared to blockers of subsequent steps of the renin-
angiotensin-aldosterone cascade. Such a concept is further
supportedbytheﬁndingthathyperaldosteronismprevalence
in resistant hypertension is as high as 20%, with obesity and
suspected OSA being the two extremely common clinical
features in this setting [21, 22].
2.4. Arterial Stiﬀening. Arterial stiﬀening constitutes a
pathophysiological substrate that promotes acceleration of
vascular aging observed in both hypertension and OSA
[23]. Increased levels of circulating vasoconstrictors [24],
enhanced subclinical inﬂammation [25], endothelial dys-
function [25], and repetitive increases of left ventricle
afterload may separately or in combination contribute to
the increasing magnitude of arterial stiﬀening. Even though
it is known that resistant hypertension is more prevalent
in the elderly, increased arterial stiﬀness observed in OSA
may also precipitate the development of the drug-resistance
phenomenon in younger ages.
3.EpidemiologicalIssues
3.1. Noninterventional Studies. In the beginning of the
present millennium Logan et al. [26] demonstrated for the
ﬁrst time in the literature the striking prevalence (82.9%)
of OSA in 41 middle-aged obese patients with “true drug-
resistant hypertension” recruited from a hospital university
hypertension clinic. Although most men with resistant
hypertension suﬀered from OSA (95.8%), among women
those not aﬀected by the syndrome (35.3%) were younger,
received less drugs, presented with a longer sleep time by
30% and less arousal movements per hour of sleep by 80%,
and ﬁnally demonstrated a higher 24-hour pulse pressure,
compared to those not aﬀected by OSA. Another surprising
ﬁnding in the same study was that almost one third of OSA
patients with resistant hypertension had a normal dipping
proﬁle, suggesting that the nondipping phenomenon in
resistant hypertension may be driven by OSA-independent
pathophysiological mechanisms.
In another cross-sectional case-control study from the
same investigational group [27], patients with drug-resistant
hypertension were compared with a group of patients with
controlled hypertension matched forage, sex, and body mass
index. Accordingly, Ruttanaumpawan et al. [27]r e p o r t e d
that those with controlled hypertension—as expected—
received fewer antihypertensive medications and the use
of diuretics was 60% less frequent with respect to those
with resistant hypertension. Moreover, the prevalence of
OSA was almost 50% more frequent in those with resistant
hypertension. Total time asleep, sleep eﬃciency, and time of
rapid-eye movement sleep were signiﬁcantly higher in those
with controlled hypertension compared to their resistant
hypertension counterparts; interestingly, only the two latter
parameters in tandem with the presence of OSA were
unadjusted determinants of resistant hypertension in the
total study population.After adjusting forconfounders, OSA
and reduced time of rapid-eye movement sleep qualiﬁed as
independent signiﬁcant determinants of resistant hyperten-
sion. Among antihypertensive medications, calciumblockers
implementation was associated with a lower amount of
rapid-eye movement sleep, suggesting that disruption of
sleep architecture might be associated in some degree with
the selection of antihypertensive drugs.International Journal of Hypertension 3
In a case-control study, Gonc ¸alves et al. [28]d e m o n -
strated that patients with resistant hypertension are aﬀected
almost 5 times more frequently by OSA—diagnosed by
portable sleep monitors—compared to their well-controlled
hypertensive counterparts matched for age, sex, and body
massindex.Finally,inaSpanisharticlebyMart´ ınez-Garc´ ıa et
al. [29], the severity of OSA diagnosed by polysomnography
as measured by the apnea/hypopnea index was associated
with the magnitude of BP levels in elderly patients with
diﬃcult-to-control hypertension and OSA after adjustment
for age and sex.
Another study reported that, among resistant hyper-
tension patients, there is a positive association between
plasma aldosterone levels and severity of OSA. However, no
correlationwas noted between OSAand aldosteronelevelsin
subjects without resistant hypertension with equally severe
OSA [30]. These ﬁndings conﬁrm the high prevalence of
OSA in resistant hypertension (85%) and are consistent with
the hypothesis that hyperaldosteronism in resistant hyper-
tension might exacerbate OSA—by promoting upper airway
edema due to sodium and ﬂuid retention—or inversely, OSA
stimulates aldosterone release, while there might even be a
bidirectional relationship in that phenomenon.
3.2. Interventional Studies. Logan et al. [31]t e s t e dt h e
therapeuticimpact ofCPAPtherapyonambulatory BPlevels
in 11 patients with drug-resistant hypertension and OSA
both at a single night’s application and after a period of
two months. CPAP eﬃciently applied for one night was
accompanied by a signiﬁcant reduction in nocturnal BP
levels. More speciﬁcally, nocturnal systolic BP exhibited a
more pronounced acute reduction compared to a more
limited reduction of the nocturnal diastolic component
(138.3 ± 6.8 to 126.0 ± 6.3mmHg versus 77.7 ± 4.5 to
72.9 ± 4.5mmHg, resp.). Additionally, CPAP use for 2
months was accompanied by an 11.0 ± 4.4mmHg decrease
in 24-hour systolic BP, whereas the nocturnal diastolic
BP was reduced signiﬁcantly by 7.8 ± 3.0mmHg. In these
lines, eﬃciently treating OSA in resistant hypertension
might be a therapeutic “add-on” option to the underlying
antihypertensive treatment to reduce BP levels within the
goal.
Inasubsequentworkon33elderlypatientswithdiﬃcult-
to-treat hypertension and OSA [32], Mart´ ınez-Garc´ ıa et al.
highlighted, along with the beneﬁcial eﬀect of CPAP on
systolic ambulatory BP levels, the fact that compliance to
CPAP therapy (>4 hours at night on CPAP) is crucial for the
eﬃcient reduction of BP. Indeed, those who tolerated CPAP
(n = 23) showed a signiﬁcant drop in mean 24-hour systolic
BP of 7.6mmHg without signiﬁcant changes in mean 24-
hour diastolic BP; however, in those who were CPAP intol-
erant (n = 10), there were no signiﬁcant changes in either
mean diurnal or nocturnal, either systolic or diastolic BP.
Lozano et al. [33] in a randomized prospective con-
trolled study evaluated the change in mean 24-hour systolic
and diastolic BP at the three-month follow-up in two
groups of patients with resistant hypertension and OSA:
29 patients under well-tolerated CPAP and appropriate
pharmacological treatment (i.e., CPAP arm) and 35 patients
under appropriate pharmacological treatment alone (i.e.,
conventional arm). The use of CPAP for three months was
accompanied by a mean reduction of almost 5mmHg in 24-
hour diastolic BP in the CPAP arm, whereas no signiﬁcant
change was observed in the arm of conventional therapy.
In those wearing the mask for at least 5.8 hours per day
signiﬁcant changes were registered in diurnal and 24-hour
diastolic BP and in 24-hour systolic BP. It is worth noting
that the beneﬁcial eﬀe c to fC P A Po nB Pl e v e l sw a so n l y
seen in those with resistant hypertension conﬁrmed with
ambulatory BP monitoring, but not in those with resistant
hypertension diagnosed only by oﬃce BP measurements.
The number of patients in the CPAP arm with a nondipping
pattern decreased signiﬁcantly from 51.7% at baseline to
24.1% at the three-month follow-up, whereas no changes
were observed in patients of the conventional arm of the
study, in line with previous ﬁndings. A ﬁnal important
issue in the Lozano et al. [33] study was that, among those
who accepted to wear the mask, the Epworth Sleepiness
scale scoring did not diﬀer between those who used CPAP
for more and less than 5.8 hours/day, suggesting that
even asymptomatic patients with resistant hypertension had
similar reductionsin BPlevelsespecially if CPAPwas applied
for more than the cut-oﬀ of 5.8 hours/day.
In a retrospective chart review study [34], medical
records of patients who had a polysomnography with CPAP
study were reviewed and among them the researchers
selectedthosewithhypertension;OSAcompliantwithCPAP;
oﬃce BP measurements obtained within three months of
enrollment, every three months for six months and at one
year after CPAP initiation. In subjects exhibiting resistant
hypertension, the use of CPAP therapy was accompanied
by a decrease in daytime BP at both 6 and 12 months
after treatment initiation, while in almost 70% of these
patients a reduction in either the dose or the number of
antihypertensive drugs used at baseline was observed. On
the contrary, patients with controlled hypertension and OSA
demonstrated no signiﬁcant change in BP levels over the
same period of time, suggesting that the eﬀect of CPAP
on BP, when the latter has been already controlled with
medication, is at least less pronounced or even absent in line
with previous ﬁndings [35, 36].
4.ClinicalDecisions: Lost inTranslationor
a Simple Rationale?
In patients with hypertension a thorough sleep history
conﬁrmed—if applicable—by the bed partner, identiﬁcation
of daytime symptoms, and a physical examination including
visualization of the pharynx are all essential steps in order to
separate those with a high clinical suspicion of OSA. How-
ever, in patients with drug-resistant hypertension establish-
ing a high or low clinical suspicion for OSA might be futile.
For example, in the context of resistant hypertension, the
use of clinical prediction tools, like the Epworth Sleepiness
Scale could not be as helpful [33]a si tm a yb ef o rt h eg e n e r a l
populationofhypertensive patients[4].Therefore, inclinical
practice, those with true drug-resistant hypertension should
be counseled to undergo polysomnography.4 International Journal of Hypertension
Along with the other diagnostic exams, in true drug-
resistant hypertension, a24-hourambulatoryBPmonitoring
should be considered valuable as it conﬁrms the oﬃce
evaluation of BP levels and possibly helps the clinician assess
the hemodynamic responsiveness to CPAP treatment better
[33].Furthermore,evaluatingthedippingpatternandnight-
time BP levels in resistant hypertension is vital for a more
comprehensive approach of the circadian BP variability, its
response to therapy, and the potential implementation of
chronotherapy issues [4].
Lifestyle modiﬁcations should always stand at the ﬁrst
line of the therapeutic procedure in resistant hypertension
associated with OSA. The importance of appropriate weight
control must be underlined, and bariatric surgery should
be encouraged if morbid obesity coexists. Additionally, the
underlying pathophysiological mechanisms activated in the
duo of resistant hypertension and OSA prompt to rigorous
sodium intake restriction [4].
In resistant hypertension complicated by OSA, CPAP
is imperative as it proved an eﬃcacious “add-on” to the
conventional pharmacological treatment and succeeded to
reverse nondipping proﬁle in most of the patients [31,
33]. In these lines, patients should be encouraged to wear
their mask every night and possibly for the whole night.
The antihypertensive eﬀect of CPAP seems to be more
prominent in those with more severe OSA or hyper-
tension, though there is limited evidence whether sleepy
and nonsleepy patients with drug resistant hypertension
beneﬁt the same in terms of BP reduction when compliant
to CPAP treatment. Although, there is limited clinical
evidence for the potential beneﬁt of mineralocorticoid
antagonistsin resistant hypertension and OSA[37], theiruse
should be considered as an additional promising therapeutic
strategy with a plausible pathophysiological background
[6, 21].
Since resistant hypertension and OSA are accompanied
either separately or in combination with highly increased
prevalence of target organ damage and adverse cardiovas-
cular outcome, combined treatment seems to be of the
highest clinical priority. Targeting on both the maximum
individual doses of antihypertensive drugs and the eﬀective
implementation of CPAP should remain the main awareness
of the physician dealing with this compound diﬃcult-to-
treat hypertensive disorder.
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